MARKET WIREReuters • 1h ago
US voters in a sour economic mood heading into midterm elections - ReutersUS voters in a sour economic mood heading into midterm elections Reuters
Why BOLD Stock slipped -0.40% Today — RQD Quant Desk Flash
$2.47 -0.40% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $2.46
Boundless Bio Inc. (BOLD) carries a Roarable Rating of D- (Sell) with 41/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D- • RED ALERT
Cap $57.3M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on BOLD Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is BOLD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, Boundless Bio Inc. (NASDAQ: BOLD) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 41/100 at a spot price of $2.47 (-0.40% 1D, market cap $57.3M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, BOLD ranks #510 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does BOLD compare to HYFT and NMAD in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), BOLD carries a Roarable D- (41/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, HYFT (MindWalk Holdings Corp.) holds a D+ grade (58/100 RQD, P/E N/A, ROIC —, cap $57.1M) and NMAD (Nomad Power Solutions Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $57.0M). Among the 5-stock peer group, BOLD leads on earnings multiple (N/A) while BOLD leads on capital efficiency (-35.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for BOLD?
▼
Per BOLD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001782303), Boundless Bio Inc. generated $0 in revenue, -$58.2M in net income, and -$47.2M in free cash flow against $157.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $2.46 (-0.26%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (41/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.2% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • D-
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D- · Rk D
Each axis scored 0–20
12M PRICE TARGET CONE-7.7% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for BOLD)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (41/100 Composite)
🔍 WHY BOLD SCORES 41/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (24% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9
▲ #2 Bullish Driver: Macro Regime Fit+10/20 pts (24% of score)
FRED Regime × Technicals: 69% of 52W Range • RSI-14 at 46.5 (NEUTRAL RANGE)
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)
Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade D$2.53-7.5% Next Q
49
Q2 (-2Q)Grade D$2.34+0.9% Next Q
46
Q3 (-1Q)Grade D$2.36+4.7% Next Q
44
CurrentGrade D-$2.47-7.2% Hist 90D α
41
Trajectory: D (49) → D- (41)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a BOLD Turnaround Squeeze
While BOLD currently carries a cautious 41/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.66) and Max Pain ($2.59) forces dealer call-delta covering toward $3.32.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $BOLD• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “BOLD Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why BOLD Stock slipped -0.40% Today — RQD Quant Desk Flash
Boundless Bio Inc. (BOLD) slipped -0.40% to $2.47, trading at 69% of its 52-week range ($0.96 – $3.16). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 69% of its 52-week range ($0.96 – $3.16) with RSI-14 at 46.5 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $2.47 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D- (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live BOLD Headlines & Catalysts
MARKET WIREReuters • 1h ago
China's foreign minister pushes for dialogue to resolve Middle East conflict - ReutersChina's foreign minister pushes for dialogue to resolve Middle East conflict Reuters
MARKET WIREReuters • 2h ago
COMMENTARY: Asia's crude oil imports back to pre-war levels but refined fuels lag - ReutersCOMMENTARY: Asia's crude oil imports back to pre-war levels but refined fuels lag Reuters
MARKET WIREReuters • 2h ago
Iranians have left Doha talks, draft proposal for US deal being circulated, official says - ReutersIranians have left Doha talks, draft proposal for US deal being circulated, official says Reuters
MARKET WIREReuters • 6h ago
Saudi civil defence sounds all-clear after alerts in southern cities - ReutersSaudi civil defence sounds all-clear after alerts in southern cities Reuters
MARKET WIREReuters • 6h ago
World's energy supply buffers have been eroded, ADNOC CEO says - ReutersWorld's energy supply buffers have been eroded, ADNOC CEO says Reuters
MARKET WIREReuters • 6h ago
Afghanistan asks US to act responsibly on deporting Afghan immigrants back home - ReutersAfghanistan asks US to act responsibly on deporting Afghan immigrants back home Reuters
MARKET WIREReuters • 7h ago
Anthropic plans to sell $3.5 billion of shares to Japan investors in IPO, filing shows - ReutersAnthropic plans to sell $3.5 billion of shares to Japan investors in IPO, filing shows Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring BOLD)
- ✓Walkthrough of BOLD's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
BOLD // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +69.18%📐 HORIZONTAL RANGE
2026-10-30O $2.53H $2.59L $2.43C $2.47VOL 47.0K
RES: $3.58SUP: $2.27SMA50: $2.66SMA200: $1.91
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
BOLD Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on BOLD today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for BOLD. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for BOLD today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BOLD)
Health Care Rank #510 of 1016
⚔️ HYFT vs BOLD Full Matrix →
1. Head-to-Head Health Care Peer Comparison (BOLD vs. HYFT, NMAD, RFL, ONCY)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Boundless Bio Inc. (BOLD) ranks #510 by composite RQD confidence (41/100, grade D-) and #728 by equity capitalization ($57.3M). Within this direct 5-issuer industry benchmark cohort, BOLD leads on earnings valuation at N/A trailing P/E, while BOLD leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. HYFT currently holds the highest overall quantitative score in the immediate peer group at 58/100 (D+) compared with BOLD at 41/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| BOLD
ACTIVE
Boundless Bio Inc. | D- | 41/100 | — | — | -35.0% | -0.40% | $57.3M | Benchmark Subject |
| HYFT MindWalk Holdings Corp. | D+ | 58/100 | — | — | — | -5.83% | $57.1M | /hyft-vs-bold → |
| NMAD Nomad Power Solutions Inc. | E | 33/100 | — | — | -35.0% | +0.56% | $57.0M | /nmad-vs-bold → |
| RFL Rafael Holdings Inc. (Class B) | E | 16/100 | — | — | -35.0% | -3.57% | $58.2M | /rfl-vs-bold → |
| ONCY Oncolytics Biotech Inc. | D | 45/100 | — | — | -35.0% | -0.54% | $56.1M | /oncy-vs-bold → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001782303In its most recent audited fiscal period (FY2025, filed 2025-12-31), Boundless Bio Inc. (BOLD) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$58.2M, operating cash flow of -$46.7M, and free cash flow of -$47.2M (+25.5% YoY). On the balance sheet, BOLD closed FY2025 with $157.1M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$58.2M | -$46.7M | -$47.2M | $157.1M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$65.4M | -$60.8M | -$63.4M | $206.4M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$49.4M | -$46.9M | -$46.9M | — | — |
3. BOLD Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs BOLD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, Boundless Bio Inc. (NASDAQ: BOLD) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 41/100 at a spot price of $2.47 (-0.40% 1D, market cap $57.3M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, BOLD ranks #510 in composite RQD confidence.
How does BOLD compare to HYFT and NMAD in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), BOLD carries a Roarable D- (41/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, HYFT (MindWalk Holdings Corp.) holds a D+ grade (58/100 RQD, P/E N/A, ROIC —, cap $57.1M) and NMAD (Nomad Power Solutions Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $57.0M). Among the 5-stock peer group, BOLD leads on earnings multiple (N/A) while BOLD leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for BOLD?
Per BOLD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001782303), Boundless Bio Inc. generated $0 in revenue, -$58.2M in net income, and -$47.2M in free cash flow against $157.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is BOLD trading relative to its 50-day, 200-day, and 52-week technical levels?
BOLD last traded at $2.47 (-0.40% on volume of 47,016 shares), positioning the stock -7.14% below its 50-day simple moving average ($2.66) and +29.32% above its 200-day simple moving average ($1.91). Across its 52-week range of $0.96 to $3.16, BOLD sits at the 68.6% percentile with a 14-day RSI of 46.5 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($2.16 to $2.78).
BOLD Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is BOLD stock moving today?
Why BOLD Stock slipped -0.40% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.